NCT07225621 2026-03-19
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
Phase 2 Recruiting
Clinical Trials
26 trialsNCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT05804370 2025-10-01
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp
Phase 3 Recruiting
NCT05736406 2025-09-11
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Recruiting
NCT04815083 2025-09-03
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Phase 3 Terminated
NCT05362409 2025-06-19
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Alpheus Medical, Inc.
Phase 1 Completed
NCT03897491 2025-05-14
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
photonamic GmbH & Co. KG
Phase 2 Active not recruiting
NCT04305470 2024-06-18
MEN-301
NX Development Corp
Phase 3 Completed
NCT01966120 2023-07-28
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02144077 2022-11-03
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02239679 2018-08-24
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02632110 2018-01-18
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT03024060 2017-11-07
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
DUSA Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT02628236 2017-09-18
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02799069 2017-04-28
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02799082 2017-04-06
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02281136 2017-01-13
Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT01475955 2016-10-28
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02209012 2016-09-23
Twelve Month Follow-Up of CP0108
DUSA Pharmaceuticals, Inc.
Completed
NCT02799030 2016-07-19
A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis
Biofrontera Bioscience GmbH
Phase 2 Completed
NCT02755142 2016-05-23
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
medac GmbH
Phase 1/2 Completed
NCT02137785 2015-09-16
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
DUSA Pharmaceuticals, Inc.
Phase 3 Completed
NCT01458587 2013-03-14
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT00241670 2012-04-26
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
medac GmbH
Phase 3 Completed
NCT00865878 2011-10-21
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
DUSA Pharmaceuticals, Inc.
Phase 2 Terminated